419 results on '"Doroshow, J."'
Search Results
2. Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy
3. Abemaciclib drug combination screening with other targeted therapies in complex multicellular tumor spheroids
4. The NADPH oxidase NOX5 protects against apoptosis in ALK-positive anaplastic large-cell lymphoma cell lines
5. CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute
6. Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome
7. 175 (PB055) - Abemaciclib drug combination screening with other targeted therapies in complex multicellular tumor spheroids
8. Phase II trial of 5-fluorouracil, high-dose leucovorin calcium, and dipyridamole in advanced prostate cancer
9. Phase II study of oxaliplatin in patients with unresectable, metastatic or recurrent hepatocellular cancer: 4169
10. Ribonucleotide reductase M1 and M2 (RR-M1, -M2), cytidine deaminase (CDA), deoxycytidine deaminase (dCDA), deoxycytidine kinase (dCK), and excision repair cross complementation - 1 (ERCC-1) expression in advanced malignancies treated with combined oxaliplatin and gemcitabine: 3456
11. Pharmakokinetische Phase-I-Studie mit Oxaliplatin (OXA) bei Patienten mit soliden Tumoren und unterschiedlichen Graden der Leberfunktionsstörung (LD): 449
12. Phase-I-Studie mit Oxaliplatin (OXA) bei Karzinom-patienten mit eingeschränkter Nierenfunktion: 267
13. Phase-I-Studie zu Oxaliplatin (OXA) in Kombination mit Taxotere (TAX): 2108
14. Phase-I-Studie zu Oxaliplatin (OXA) in Kombination mit Gemcitabin (GEM): California Consortium Trial: 381
15. Genomic profiling of three pathways through molecular profiling-based assignment of cancer therapy (NCI- MPACT)
16. Erratum: CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute
17. Pharmacokinetics of High Dose Continuous Infusion (6S)-Folinic Acid in Humans
18. Role of Oxygen Radical Formation in Anthracycline Cardiac Toxicity
19. Role of Reactive Oxygen Production in Doxorubicin Cardiac Toxicity
20. Anthracycline-Enhanced Cardiac Oxygen Radical Metabolism
21. Phase I trial of oral 5-fluoro-2′-deoxycytidine with oral tetrahydrouridine in patients with advanced solid tumors
22. 448PD - Genomic profiling of three pathways through molecular profiling-based assignment of cancer therapy (NCI- MPACT)
23. Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy
24. First-in-human trial of 4'-thio-2'-deoxycytidine (TdCyd) in patients with advanced solid tumors
25. Application of Molecular Profiling in Clinical Trials for Advanced Metastatic Cancers
26. Anthracycline-Enhanced Cardiac Oxygen Radical Metabolism
27. Utility of F-fluoroestradiol (F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy.
28. 248 Use of ATR inhibitor in combination with topoisomerase I inhibitor kills cancer cells by disabling DNA replication initiation and fork elongation
29. 232 Development of a targeted NGS assay system for patient enrollment to the NCI-MATCH study
30. 269 - Phase I trial of oral 5-fluoro-2′-deoxycytidine with oral tetrahydrouridine in patients with advanced solid tumors
31. 411TiP - First-in-human trial of 4'-thio-2'-deoxycytidine (TdCyd) in patients with advanced solid tumors
32. MC13-0060 Analytical validation of the MPACT assay, a targeted next generation sequencing clinical assay for cancer patient treatment selection
33. Implementation of Timeline Reforms Speeds Initiation of National Cancer Institute-Sponsored Trials
34. L1.1 Shortening the Timeline for Cancer Drug Development
35. Lectures
36. CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute
37. Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer
38. Development and validation of biomarker assays to assess pharmacodynamic modulation of MET.
39. Standard terms of agreement for research trials (START): A joint National Cancer Institute (NCI) and CEO-roundtable Life Sciences Consortium (LSC) project.
40. Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca).
41. Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk locally advanced/inflammatory and metastatic breast cancer.
42. The Cancer Therapy Evaluation Program’s (CTEP) implementation of the Operational Efficiency Working Group (OEWG) recommendations.
43. Merrill Jon Egorin, MD, 1948–2010
44. 20 Re-inventing the methodology of early drug development
45. A pilot trial of oral topotecan (TPT) in patients with refractory advanced solid neoplasms expressing HIF-1α.
46. A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors.
47. Pharmacodynamic response in phase I combination study of ABT-888 and topotecan in adults with refractory solid tumors and lymphomas.
48. A phase I study of ABT-888 (A) in combination with metronomic cyclophosphamide (C) in adults with refractory solid tumors and lymphomas.
49. Phase I study of vandetanib (V) and bevacizumab (B) combination therapy evaluating the VEGF and EGF signal transduction pathways in adults with solid tumors and NHL
50. A phase II study of multikinase inhibitor sorafenib in patients with relapsed non-small cell lung cancer (NSCLC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.